Trends in Kampo Medicine Usage As Supportive Care During Anticancer Drug Treatment in Japanese Patients: A Nationwide Cohort Analysis from Fiscal Years 2015 to 2021

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2025 Feb 25

PMID 39996900

Authors

Hiroaki Ohta

Takeo Yasu

Affiliations

Soon will be listed here.

Abstract

The adverse effects of anticancer drugs significantly impact the quality of life of patients undergoing chemotherapy, necessitating evidence-based supportive therapies. In Japan, Kampo medicines, traditional Japanese herbal therapies used for relief of various symptoms, have been widely used as complementary and alternative treatments for cancer, despite limited evidence regarding their efficacy and safety. Thus, we investigated the actual use of Kampo medicines as supportive care in patients undergoing anticancer drug treatment and evaluated the trends in prescription according to year. We analyzed 89,141 cancer drug therapy cases registered in the Japan Medical Data Center database between April 2014 and July 2022, excluding those with a history of Kampo medicine prescriptions before the first prescription of antineoplastic drugs. We assessed the trends in prescription according to sex, age group (<50, 50-74, and ≥75 years), and cancer type subgroup using the Cochran-Armitage trend test. Approximately 23.7% of patients were prescribed Kampo medicines during anticancer drug treatment. Since 2014, a decrease in the prescription of Kampo medicines during anticancer treatment has been observed regardless of sex, age, or cancer type. These findings suggest that recent negative reports on the efficacy and safety of Kampo medicines in cancer care may have influenced this trend.

References

Matsumura Y, Futagami M, Baba T, Soeda S, Watari H, Terada Y . Effectiveness of the Traditional Japanese Medicine Goshajinkigan in Preventing Paclitaxel-Induced Peripheral Neuropathy: A Multicenter Randomized Comparative Trial. Integr Cancer Ther. 2024; 23:15347354241278635. PMC: 11403691. DOI: 10.1177/15347354241278635. View

Lalla R, Bowen J, Barasch A, Elting L, Epstein J, Keefe D . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120(10):1453-61. PMC: 4164022. DOI: 10.1002/cncr.28592. View

Ohno T, Yanai M, Ando H, Toyomasu Y, Ogawa A, Morita H . Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans. Clin Exp Gastroenterol. 2012; 4:291-6. PMC: 3254207. DOI: 10.2147/CEG.S26297. View

Kuchta K, Cameron S . Phytotherapy for Cachexia: Where Do We Stand?. Front Pharmacol. 2020; 11:917. PMC: 7360856. DOI: 10.3389/fphar.2020.00917. View

Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M . Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005; 23(12):2645-54. DOI: 10.1200/JCO.2005.04.126. View

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K . Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2017; 124(3):606-616. PMC: 5814824. DOI: 10.1002/cncr.31128. View

Akamaru Y, Takahashi T, Nishida T, Omori T, Nishikawa K, Mikata S . Effects of daikenchuto, a Japanese herb, on intestinal motility after total gastrectomy: a prospective randomized trial. J Gastrointest Surg. 2015; 19(3):467-72. DOI: 10.1007/s11605-014-2730-y. View

Arai I . Clinical studies of traditional Japanese herbal medicines (Kampo): Need for evidence by the modern scientific methodology. Integr Med Res. 2021; 10(3):100722. PMC: 8181179. DOI: 10.1016/j.imr.2021.100722. View

Kessel K, Lettner S, Kessel C, Bier H, Biedermann T, Friess H . Use of Complementary and Alternative Medicine (CAM) as Part of the Oncological Treatment: Survey about Patients' Attitude towards CAM in a University-Based Oncology Center in Germany. PLoS One. 2016; 11(11):e0165801. PMC: 5094772. DOI: 10.1371/journal.pone.0165801. View

10.

Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R . Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol. 2014; 73(5):1047-54. PMC: 4000413. DOI: 10.1007/s00280-014-2440-x. View

11.

Motoo Y, Yukawa K, Hisamura K, Tsutani K, Arai I . Internet survey on the provision of complementary and alternative medicine in Japanese private clinics: a cross-sectional study. J Integr Med. 2018; 17(1):8-13. DOI: 10.1016/j.joim.2018.11.003. View

12.

Katsuno H, Maeda K, Kaiho T, Kunieda K, Funahashi K, Sakamoto J . Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902). Jpn J Clin Oncol. 2015; 45(7):650-6. PMC: 4485603. DOI: 10.1093/jjco/hyv056. View

13.

Jacobsen P, Nipp R, Ganz P . Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. Am Soc Clin Oncol Educ Book. 2017; 37:674-683. DOI: 10.1200/EDBK_175673. View

14.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

15.

Skou S, Mair F, Fortin M, Guthrie B, Nunes B, Miranda J . Multimorbidity. Nat Rev Dis Primers. 2022; 8(1):48. PMC: 7613517. DOI: 10.1038/s41572-022-00376-4. View

16.

Yokoyama S, Nakagawa C, Hosomi K . Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. Support Care Cancer. 2021; 30(2):1765-1773. DOI: 10.1007/s00520-021-06585-z. View

17.

Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K . Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003; 51(5):403-6. DOI: 10.1007/s00280-003-0585-0. View

18.

Jeong J, Ryu B, Kim J, Park J, Choi W, Yoon S . Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther. 2010; 9(4):331-8. DOI: 10.1177/1534735410383170. View

19.

Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T . Data resource profile: JMDC claims databases sourced from Medical Institutions. J Gen Fam Med. 2020; 21(6):211-218. PMC: 7689231. DOI: 10.1002/jgf2.367. View

20.

Suzuki S, Obara T, Ishikawa T, Noda A, Matsuzaki F, Arita R . Prescription of Kampo Formulations for Pre-natal and Post-partum Women in Japan: Data From an Administrative Health Database. Front Nutr. 2021; 8:762895. PMC: 8633842. DOI: 10.3389/fnut.2021.762895. View